Tetra Bio-pharma Inc.

TBPMQ

$0.00May 03, 2021Apr 29, 2026
Health CarePharmaceuticals$0M
MVM
+$0.0M
PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Chart Start
$0.40
2021
Since 2021
-100.0%
vs SPY +70.2%
All-time High
$0.44 · May 2021
-100.0% from peak
MVM Rank
#175 of 297
Pharmaceuticals
Reaction Win Rate
31%
4 of 13 events

Tetra Bio-pharma Inc. has returned -100.0% from $0.40 since 2021, trailing SPY's +70.2% over the same period. The stock hit an all-time high of $0.44 in May 2021 and is currently 100.0% below that level. Of 13 tracked news events, 31% produced a positive market-adjusted return.

How to use this page
1Company Research Snapshot

Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.

2Company Q&A

Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.

3News & Events

Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.

Company Q&AShow ▼
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2023-08-01-55.8%newsSeeking AlphaTetra Bio-Pharma files for bankruptcy in Canada
2023-08-01-55.8%newsTheNewswireTetra Bio-Pharma Voluntary Bankruptcy - TheNewswire
2021-05-28-17.5%newsSeeking AlphaTetra Bio reports clinical advancements and establishment of ATM equity program
2022-02-14-13.4%expansionSeeking AlphaAvicanna and Tetra Bio-Pharma enter into a strategic partnership
2021-10-05+13.3%expansionProactive financial newsTetra Bio-Pharma says its first cannabinoid-derived medicine REDUVO is a ‘major milestone’ as it gears up to launch it - Proactive financial news
2022-09-06-11.2%newsSeeking AlphaTetra, Cellvera team up to develop ARDS-003/favipiravir combo for COVID-19
2021-07-12-3.8%newsSeeking AlphaTetra Bio-Pharma accelerates REBORN1 trial with approved amendments for oral opioids
2021-10-21-3.5%newsSeeking AlphaEMA grants positive opinion on Tetra Bio-Pharma's Qixleef Orphan Drug Designation application
2022-03-08+3.5%legalSeeking AlphaTetra Bio-Pharma granted Canadian regulatory nod to amend cannabidiol trial
2022-08-12-3.3%newsSeeking AlphaTetra secures up to C$6M financing for drug development, debt repayment
2021-06-02+2.4%earningsSeeking AlphaHealth Canada accepts Tetra Bio-Pharma's new drug submission for REDUVO for review
2022-02-16+2.2%newsSeeking AlphaTetra Bio-Pharma gets approval for C$4.5M loan from Qubec authority
2022-08-10-1.3%newsSeeking AlphaTetra Bio-Pharma ARDS-003 shows promise against COVID-19 in mice model
tickerdossier.comtickerdossier.substack.com